3 unknown, 1 completed, 1 not yet recruiting, 1 recruiting. 4 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Completed 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
Follow Relapsed or Refractory Acute Lymphoblastic Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Lymphoblastic Leukemia trials Research Report on Relapsed or Refractory Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
| Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia ssCART-19 Cells, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 18 | 2021-04-09 | 2023-09-21 |
| Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia single dose of CNCT19 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 100 | 2020-12-24 | 2025-08-08 |
| A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia single dose of CNCT19 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | Completed | Juventas Cell Therapy Ltd. | 10 | 2020-03-13 | 2023-03-28 |
| A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL C-CAR-011 - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Shanghai AbelZeta Ltd. | 20 | 2017-01-01 | 2017-01-20 |
| Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia MLN9708, Vincristine, Doxorubicin - Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma | Phase 1 | Terminated | Ehab L Atallah | 5 | 2013-06-01 | 2020-01-22 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Recurrence (7) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1)
Disease Attributes (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia (7) · Leukemia, Lymphoid (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Leukemia, Myeloid (1)
Cyclophosphamide (2) · fludarabine (2) · Calcium Dobesilate (1) · Dexamethasone (1) · Doxorubicin (1) · Vincristine (1) · ixazomib (1) · liposomal doxorubicin (1)
Juventas Cell Therapy Ltd. (2) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (2) · Ehab L Atallah (1) · Shanghai AbelZeta Ltd. (1) · Zhujiang Hospital (1)
China (6) · United States (1)
Jianxiang Wang, Dr. (2) · Ehab L Atallah, MD (1) · Li Yu (1)